Letter to the editor, "Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications"

Harmen R. Moes; Erik Buskens; Teus van Laar

doi:10.1016/j.parkreldis.2022.03.014

Letter to the editor, "Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications"

Harmen R. Moes^*, Erik Buskens, Teus van Laar

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

1 Citation (Scopus)

10 Downloads (Pure)

Abstract

The MANAGE-PD tool may help general neurologists in deciding whether a patient with advanced Parkinson's disease should be referred for an advanced therapy. Although the development and clinical validation of MANAGE-PD would appear to serve an important need, we urge the reader to be aware of several methodological concerns.

Original language	English
Pages (from-to)	99-100
Number of pages	2
Journal	Parkinsonism & Related Disorders
Volume	97
Early online date	25-Mar-2022
DOIs	https://doi.org/10.1016/j.parkreldis.2022.03.014
Publication status	Published - Apr-2022

Keywords

Parkinson's disease
Advanced therapy
Patient identification
MANAGE-PD
Decision Support Techniques
Levodopa-carbidopa intestinal gel (LCIG)
Deep brain stimulation (DBS)
Continuous subcutaneous apomorphine infu-sion (CSAI)
PREDICTION

Access to Document

10.1016/j.parkreldis.2022.03.014

Letter to the editor, “Validation and clinical value of the MANAGE-PD tool_ A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications”Final publisher's version, 915 KBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{8984325a0cc34de891b3a5e9cb664b0b,

title = "Letter to the editor, {"}Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications{"}",

abstract = "The MANAGE-PD tool may help general neurologists in deciding whether a patient with advanced Parkinson's disease should be referred for an advanced therapy. Although the development and clinical validation of MANAGE-PD would appear to serve an important need, we urge the reader to be aware of several methodological concerns.",

keywords = "Parkinson's disease, Advanced therapy, Patient identification, MANAGE-PD, Decision Support Techniques, Levodopa-carbidopa intestinal gel (LCIG), Deep brain stimulation (DBS), Continuous subcutaneous apomorphine infu-sion (CSAI), PREDICTION",

author = "Moes, {Harmen R.} and Erik Buskens and {van Laar}, Teus",

year = "2022",

month = apr,

doi = "10.1016/j.parkreldis.2022.03.014",

language = "English",

volume = "97",

pages = "99--100",

journal = "Parkinsonism & Related Disorders",

issn = "1353-8020",

publisher = "Elsevier",

}

Letter to the editor, "Validation and clinical value of the MANAGE-PD tool : A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications". / Moes, Harmen R.; Buskens, Erik ; van Laar, Teus.

In: Parkinsonism & Related Disorders, Vol. 97, 04.2022, p. 99-100.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Letter to the editor, "Validation and clinical value of the MANAGE-PD tool

T2 - A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications"

AU - Moes, Harmen R.

AU - Buskens, Erik

AU - van Laar, Teus

PY - 2022/4

Y1 - 2022/4

N2 - The MANAGE-PD tool may help general neurologists in deciding whether a patient with advanced Parkinson's disease should be referred for an advanced therapy. Although the development and clinical validation of MANAGE-PD would appear to serve an important need, we urge the reader to be aware of several methodological concerns.

AB - The MANAGE-PD tool may help general neurologists in deciding whether a patient with advanced Parkinson's disease should be referred for an advanced therapy. Although the development and clinical validation of MANAGE-PD would appear to serve an important need, we urge the reader to be aware of several methodological concerns.

KW - Parkinson's disease

KW - Advanced therapy

KW - Patient identification

KW - MANAGE-PD

KW - Decision Support Techniques

KW - Levodopa-carbidopa intestinal gel (LCIG)

KW - Deep brain stimulation (DBS)

KW - Continuous subcutaneous apomorphine infu-sion (CSAI)

KW - PREDICTION

U2 - 10.1016/j.parkreldis.2022.03.014

DO - 10.1016/j.parkreldis.2022.03.014

M3 - Comment/Letter to the editor

C2 - 35390721

SN - 1353-8020

VL - 97

SP - 99

EP - 100

JO - Parkinsonism & Related Disorders

JF - Parkinsonism & Related Disorders

ER -